Precision medicine in Alzheimer’s Disease: integration of resilience metrics and risk factors – AD-resilience
A promising path for developing precision medicine in age-related diseases is to take into account the role of disease resistance mechanisms (resilience) in addition to that of disease drivers and risk factors. AD-resilience will accelerate the development of precision medicine for patients that face Alzheimer's disease thanks to an innovative approach that is based on rich data and precision machine-learning to account for the role of resilience over pathobiology, enabling prognosis and facilitating therapeutic innovation.
Project coordination
Christian NERI (Adaptation Biologique et Vieillissement)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partner
LPSM Sorbonne Université
B2A Adaptation Biologique et Vieillissement
DMU Geriatrie Paris Sud MALADIE D'ALZHEIMER : MARQUEURS GENETIQUES ET VASCULAIRES, NEUROPSYCHOLOGIE
DMU Paris Nord DMU APHP.Nord : NEUROSCIENCES ADULTES
Help of the ANR 439,687 euros
Beginning and duration of the scientific project:
February 2022
- 48 Months
